scholarly journals Renewing An Old Interest: Pituitary Folliculostellate Cells

Author(s):  
P.R. Le Tissier ◽  
P. Mollard
2008 ◽  
Vol 116 (09) ◽  
Author(s):  
E Corrêa-de-Santana ◽  
M Theodoropoulou ◽  
B Fröhlich ◽  
M Paez-Pereda ◽  
JL Monteserin Garcia ◽  
...  

1993 ◽  
Vol 41 (7) ◽  
pp. 955-960 ◽  
Author(s):  
B L Lee ◽  
G Unabia ◽  
G Childs

We previously found follistatin (FS) mRNA in gonadotropes [predominantly in cells with luteinizing hormone (LH) antigens] and folliculostellate cells (with S100 antigens) in diestrus rats pituitaries. However, earlier in the cycle, when percentages of gonadotropes are lowest, percentages of cells expressing FS are 1.5-2-fold higher than in diestrus. This study was designed to detect FS mRNA and other pituitary antigens to identify the additional cells with dual in situ hybridization and immunolabeling protocols. The mRNA was detected with biotinylated complementary oligonucleotide probes and avidin-biotin-peroxidase complexes. Significant labeling for FS mRNA was found in cells with the following antigens: growth hormone (GH) (7% of pituitary cells); prolactin (PRL) (5%); S100 protein (5%); follicle-stimulating hormone (FSH beta) (4%); LH beta (3%); and thyroid-stimulating hormone (TSH beta) (3%). Optimal conditions for detection included: overnight plating of > 50,000 cells/well (24-well tray) in media containing 10% fetal bovine serum; hybridization at 37 degrees C; and fixation in 2% glutaraldehyde. Whereas FS is expressed predominantly by LH gonadotropes at midcycle, FS mRNA can be expressed by all types of antigen-bearing cells earlier in the cycle. Its function in the pituitary may relate to its role in binding activin, which would result in inhibition of FSH release. However, since activin inhibits secretion of GH, PRL, and adrenocorticotropin (ACTH), FS may also control activin's effects on these cells. The FS-expressing cells may therefore be paracrine or autocrine regulators.


2019 ◽  
Vol 63 (1) ◽  
Author(s):  
Ana Silvia Corlan ◽  
Anca Maria Cîmpean ◽  
Eugen Melnic ◽  
Marius Raica ◽  
Simona Sarb

Vascular endothelial growth factor (VEGF), its inhibitory splice variant, VEGF165b and Endocrine Gland derived VEGF (EG-VEGF) have a controversial role in pituitary gland. We aim to study VEGF, VEGF165b and EG-VEGF expression in pituitary adenomas. A significant correlation was found between growth hormone (GH) and VEGF secretion (P=0.024). For prolactinomas, VEGF and prolactin expression, had a P-value of 0.02 for Kendall coefficient and a P-value of 0.043 for the Spearman coefficient. VEGF-mRNA amplification was detected in both tumor cells and folliculostellate cells. VEGF165b was positive in 16.66% of pituitary adenomas. EG-VEGF was significantly correlated with prolactin (P=0.025) and luteinizing hormone (P=0.028). Our data strongly support VEGF, VEGF165b and EG-VEGF as important players of pituitary adenomas tumorigenesis. Particular hormonal milieu heterogeneity, special vascular network with an unusual reactivity to tumor growth correlated with variability of VEGF, VEGF165b and EG-VEGF secretion may stratify pituitary adenomas in several molecular groups with a direct impact on therapy and prognosis.


1991 ◽  
Vol 2 (3) ◽  
pp. 155-160 ◽  
Author(s):  
Hiroshi Nishioka ◽  
Josefina F. Llena ◽  
Asao Hirano

2016 ◽  
Vol 49 (6) ◽  
pp. 171-179 ◽  
Author(s):  
Rahimi Syaidah ◽  
Takehiro Tsukada ◽  
Morio Azuma ◽  
Kotaro Horiguchi ◽  
Ken Fujiwara ◽  
...  

2000 ◽  
Vol 167 (1) ◽  
pp. 25-32 ◽  
Author(s):  
G.M. Cónsole ◽  
S.B. Jurado ◽  
F.L. Riccillo ◽  
C.L.A. Gómez Dumm

Sign in / Sign up

Export Citation Format

Share Document